Advances in HSP27 and HSP90-targeting strategies for glioblastoma.
J Neurooncol
; 127(2): 209-19, 2016 Apr.
Article
em En
| MEDLINE
| ID: mdl-26842818
ABSTRACT
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. There is a critical need for novel strategies to abolish the molecular mechanisms that support GBM growth, invasion and treatment resistance. The heat shock proteins, HSP27 and HSP90, serve these pivotal roles in tumor cells and have been identified as effective targets for developing therapeutics. Natural and synthetic inhibitors have been evaluated in clinical trials for several forms of systemic cancer but none as yet for GBM. This topic review summarizes the current preclinical evidence and rationale to define the potential of HSP27 and HSP90 inhibitors in GBM management.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Glioblastoma
/
Proteínas de Choque Térmico HSP90
/
Proteínas de Choque Térmico HSP27
/
Terapia de Alvo Molecular
/
Antineoplásicos
Limite:
Adult
/
Humans
Idioma:
En
Revista:
J Neurooncol
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Canadá